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Summary Background & aims: The variations of bone mineral density (BMD) during
home parenteral nutrition (HPN) and their relationship with general, life style,
primary disease and HPN risk factors were investigated by a follow-up study.
Design: Patients who had BMD assessment in a previous cross-sectional survey
underwent a 2nd BMD at femoral neck (FN) and lumbar spine (LS). Data about risk
factors were collected by a structured questionnaire. BMD Z-score (number of
standard deviations from normal values corrected for sex and age) and the
annualized percent BMD change were analysed.
Results: Sixty-five adult patients were enrolled (follow-up: 18.175.5 months).
The mean BMD Z-score significantly increased at the LS (P ¼ 0:040) and remained
unchanged at FN. In multiple regression analysis, the variations of the LS Z-score
during HPN negatively correlated with the female sex (P ¼ 0:021) and the age at
starting HPN (P ¼ 0:022). The analysis of the annualized percent BMD change
confirmed the results obtained by the analysis of the Z-score. No factor was
associated with BMD variation at FN.
Conclusions: HPN was not associated with a decrease of BMD in most of the
patients; LS BMD Z-score variations were related to general risk factors rather than
to HPN factors, showing a negative association with age and female sex.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
Patients on long-term home parenteral nutrition
(HPN) may develop a metabolic bone disease whose
pathogenesis appears multifactorial.1–5 The preva-
lence and the severity of bone disease in HPN for
benign chronic intestinal failure have recently been
evaluated by a cross-sectional multicentre study
assessing the bone mineral density (BMD) in adult
patients.6 Bone disease was present in 84% of the
patients according to the BMD T-score (the number
of standard deviations from the mean BMD value of
sex-matched healthy young adults) and in 62%
according to the BMD Z-score (the number of
standard deviations from the mean BMD value of
sex and age-matched healthy controls); in one-half
of the patients, the bone mineral density was of
severe degree. Both the BMD T- and Z-scores
appeared predictive of the risk of fracture. The
prevalence of bone disease was similar between
males and females, was greater in post-menopausal
than in pre-menopausal women and did not differ
between the primary gastrointestinal disease sub-
groups. The femoral neck (FN) BMD Z-score was
positively associated with body mass index (BMI)
and the lumbar spine (LS) BMD Z-score was
positively associated with patient age at starting
HPN. No factors directly due to HPN were found to
be significantly related to the BMD Z-score.
A few follow-up studies7–10 on variations of BMD
during HPN were performed by single centres and
included small patient groups. The results were not
consistent among the various studies and the small
number of patients hampered an extensive analysis
of risk factors for loss of bone mass. In order to
further analyse the variations of BMD during HPN
for benign intestinal failure and their relationships
with potential clinical risk factors, a multicentre
follow-up study was performed, including patients
enrolled in the previous cross-sectional survey.
Material and methods
Study protocol
A multicentre follow-up study was carried out
which enrolled patients who had undergone BMD
assessment (1st BMD) in a previous cross-sectional
survey6 on the prevalence of bone disease in HPN.
All the centres participating in the previous survey
were invited to contribute to the present study.
Patients were included in the follow-up study if
all the following criteria were met:
(a) having been in the previous cross-sectional
survey;
(b) having been routinely followed by the centre;
(c) having undergone a second BMD assessment
(2nd BMD) at least 9 months after the 1st BMD
assessment;
(d) having had both the BMD assessments per-
formed by the same dual-energy X-ray absorp-
tiometry (DEXA) instrument (Hologic QDR 1000
or 4500, Norland XR36, Lunar DPX) and at the
same anatomical site (lumbar spine or femoral
neck).
The participating centres were also asked to
review the records of the patients included in the
previous cross-sectional survey, in order to search
for the results of the BMD assessment performed
immediately before or after the beginning of HPN
(within 1 month) by the same DEXA instrument used
for the 1st BMD (baseline BMD).
Data collection
The patient records were reviewed using a struc-
tured questionnaire. The following data were
collected with respect to the 1st and the 2nd BMD
and to the follow-up period:
General factors and life-style factors: Age
(years); sex; menopausal state; body weight (BW);
BMI (kg/m2); no. of significant variations of BW
(75 kg) during the follow-up; rehabilitation degree
according to the Mughal and Irving classification11
(grade 1–4¼ best to poorest); no. of changes of the
rehabilitation degree during the follow-up; cigar-
ette smoking.
Underlying disease factors: Primary disease and
its duration before starting HPN; age at starting
HPN; cause of the intestinal failure; intestinal
function (% of fat malabsorption); oral energy
intake (dietary history); characteristics of the oral
diet (free, low fat, low fibre, liquid, clear liquid, no
oral food); systemic inflammation (ESRX20, serum
CRP4normal or WBC X9000/mm3: 0%, 25%, 50%,
75% or 100% of the duration of the follow-up);
hospital stays: no. and duration (days); drugs:
corticosteroids, immunosuppressive, oral calcium,
calcitonin, anabolic steroids, bisphosphonates, oral
or i.m. vitamin D, diuretics, SERMS, estrogens:
dosage and duration of the treatment during the
follow-up); presence of organ failure (liver, renal);
and surgical procedures.
HPN factors: Total duration of HPN; character-
istics of the HPN programme during the follow-up;
no. of days of infusion/week; length of infusion (h/
day of infusion); ratio between energy supplied
weekly by HPN (kJ/day of infusion no. of infusions
per week) and weekly basal energy expenditure
(BEE) evaluated by the Harris–Benedict formula
(BEE 7); amino acids, glucose, fats: g/kg BW/day
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of infusion; Ca, P, Mg, Na and acetate: mmol/day of
infusion; Ca/P ratio; vitamins and trace metals: no.
of infusions/week; and no. of central venous
catheter (CVC) major complications (catheter
infections, thrombosis). Information about serum
and parenteral solution aluminium concentrations
were also asked.
Bone disease diagnosis and classification
The BMD Z-score (number of standard deviations
from normal values corrected for sex and age) and
the annualized percent BMD change were analysed.
The Z-score was classified as:
* normal: a Z-score within 1 SD;
* reduced: a Z-score below 1 SD but less than
2 SD;
* severely reduced: a Z-score equal or below
2 SD.
At all centres, the BMD Z-score reference values
were those provided by the manufacturer of the
absorptiometer.
The annualized percent BMD change was the
observed BMD change (g/cm2) divided by the time
of observation for each individual patient, equal-
ized for 365 days. In each centre, the precision of
the DEXA instrument was assessed by spine phan-
tom BMD CV which was o1% in all the centres
during the study period.
The occurrence of bone pain and bone fractures
during the follow-up periods were noted.
Statistics
Data are reported as mean7standard deviations
and range (within parenthesis). Differences be-
tween means were analysed by the Mann–Whitney
U-test. Differences between frequencies were
analysed by the w2 test. Relationships were ana-
lysed using Pearson’s simple regression and by
backward multiple regression analyses. The SSPS/
PCþ statistical package (SSPS Inc. Chicago, USA)
was used for the analyses. Two-tailed P-values
o0.05 were accepted as significant.
Results
Patient population
Six out of the nine centres which contributed to the
first cross-sectional survey participated in the
present study. A total of 65 patients of Caucasian
race met the criteria for inclusion, which repre-
sented 45% of the patient population included by
these centres in the first survey. The reasons for
patient exclusion from the analysis were: cessation
of HPN during the follow-up, lack of patient
informed consent, 2nd BMD assessment performed
less than 9 months from the 1st BMD or performed
by a DEXA instrument different from that used for
the baseline BMD.
In all the patients, the indication for the 1st BMD
assessment had been routine follow-up or partici-
pation in the cross-sectional study. DEXA- scans
were performed with the following instruments:
Hologic (QDR 1000 or 4500) in 29 patients (44.6%);
Norland (XR36) in 22 (33.9%); and Lunar (DPX) in 14
(21. 5%). The characteristics of the patients at the
1st BMD are reported in Table 1.
The 2nd BMD was performed after a mean
of 18.175.5 (9–33) months from the 1st BMD.
The site of the assessment was the LS in 50 patients
and the FN in 44. Tables 2 and 3 report
the characteristics of the patients, of the
underlying disease and of the HPN programme
during the follow-up, except for the serum and the
parenteral solution aluminium concentrations
which were obtained only in two and five patients,
respectively.
Variations of the BMD Z-score and symptoms
of bone disease during follow-up
Data are reported in Table 4. The BMD Z-score
increased in more than one-half of the patients
at both the LS and the FN. Simple regression
between Z-scores and annualized percent BMD
changes was R ¼ 0:867 (Po0:001) at LS and R ¼
0:855 (Po0:001) at FN. The mean BMD Z-score
significantly increased at the LS (P ¼ 0:040) and
remained unchanged at the FN (P ¼ 0:520). In the
group of patients who had BMD assessment at both
sites, no significant relationship was observed
between the Z-score variations (R ¼ 0:224;
P ¼ 0:217).
During the follow-up, 40.0% of the patients
complained of bone pain and three patients (post-
menopausal women) had five non-traumatic bone
fractures (spine, 2; rib, 1; forearm, 1). At the 1st
BMD assessment, the Z-scores of patients with
symptoms of bone disease during the follow-up
were similar to the Z-scores of the asymptomatic
patients. During the follow-up, the mean variations
of the Z-scores were negative in the subgroup
of symptomatic patients and positive in the
group of asymptomatic patients, the difference
being statistically significant only for the lumbar
spine Z-score. In two out of the three patients who
had bone fractures, the 1st BMD Z-scores were
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o2.5 at both sites of assessment, whereas the
third patient had only LS assessment which was
1.46.
Comparisons in patient subgroups
General factors, life style, primary disease and
HPN-related factors as well as the BMD Z-score at
baseline were compared between the two sub-
groups of patients who showed a decrease of the
BMD Z-score and those who showed an increase or
no change during follow-up.
At the FN, the two subgroups differed only
with respect to the primary diseases (Tables 5–7).
The mean annualized percent BMD change did
not differ between pre-menopausal (0.9873.09)
and post-menopausal (0.2575.18) women
(P ¼ 0:397).
At the LS, the subgroup which showed a decrease
and the subgroup which showed an increase or no
change of the BMD Z-score significantly differed
with respect to the Z-score value at the 1st BMD,
age at the 1st BMD, sex, degree of rehabilitation at
the 2nd BMD, age at starting HPN, primary disease,
ARTICLE IN PRESS
Table 1 Characteristics of the patient population at the 1st BMD assessment.
No. 65
Age (years) 51.9715.3 (20–76)
Males/females (no.) 26/39
Post-menopausal females (no.) 25
Duration of HPN (months) 72.1761.9 (5–293)
Age at starting HPN (years) 46.3716.5 (4–74)
Primary disease (no. and %)
Crohn’s 13 (20.0%)
Mesenteric ischaemia 30 (46.2%)
Othersa 22 (33.8%)
Age at diagnosis of the primary disease (years) 42.6717.8 (3–73)
Duration of the primary disease before HPN (months) 41.0758.1 (0–217)
Cause of intestinal failure (no. and %)
Short bowel 58 (89.2%)
Motility disorder 5 (7.7%)
Extensive disease 1 (1.5%)
Fistulas 1 (1.5%)
BMI (kg/m2) 20.973.1 (9.8–28.4)
Rehabilitation degree (best to poorest: 1–4) 1.9270.97 (1–4)
BMD Z-Score at lumbar spine (in 52 pts.) 1.4871.38 (4.15 to þ 2.07)
41 21 (40.4%)
Between p1 and o2 10 (19.2%)
p2 21 (40.4%)
BMD Z-Score at femoral neck (in 48 pts.) 1.0271.38 (3.99 to þ 2.70)
41 23 (47.9%)
Between p1 and o2 14 (29.2%)
p2 11 (22.9%)
HPN¼home parenteral nutrition.
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
aRadiation enteritis, 6; pseudo-obstruction, 3; others, 13.
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duration of the primary disease before starting
HPN, the number of CVC infections per
patient, number of patients having hospitalization
and the number of hospitalization days per patient
during the follow-up (Tables 8–10). The mean
annualized percent BMD change was slightly
positive in pre-menopausal (0.2274.96) and
negative in post-menopausal (3.0574.01) women
(P ¼ 0:157).
Regression analyses in the whole group
A significantly positive correlation was observed
between the age at starting HPN and the LS BMD
ARTICLE IN PRESS
Table 2 Characteristics of the patient population (65 pts.: 26 males and 39 females) at the 2nd BMD assessment
and during the follow-up (between the 1st and the 2nd BMD).
Data at the 2nd BMD
Duration of HPN (months) 89.5762.5 (21–314)
Age of the patients (years) 53.2715.4 (22–77)
Post-menopausal females (no.) 27
BMI (kg/m2) 21.172.59 (12.1–26.7)
Rehabilitation degree (best to poorest: 1–4) 1.7270.88 (1–4)
Duration of the follow-up
9–11 months (no. of pts. and %) 6 (9.2%)
12–17 months (no. of pts. and %) 25 (38.5%)
18–23 months (no. of pts. and %) 22 (33.8%)
X23 months (no. of pts. and %) 12 (18.5%)
Data during the follow-up
Variations of body weight75 kg
No. of patients 21
No. of variations/patient 2.9571.83 (1–6)
Variations of rehabilitation degree
No. of patients 5
No. of variations/patient 1.070.0
Cigarette smoking (no. of pts. and %) 9 (13.8%)
Patients receiving drugs (no. and %)
Corticosteroids 5 (7.7%)
Immunosuppressive 1 (1.5%)
Diuretics 6 (9.2%)
Oestrogenic hormones 3 (4.6%)
Oral calcium 23 (35.4%)
Bisphosphonates 14 (21.5%)
Vitamin D, i.m. 19 (29.2%)
Vitamin D, oral 20 (30.8%)
Morbidity (no. of pts. and %)
Chronic renal failure 7 (10.7%)
Surgical interventiona 4 (6.1%)
Deep vein thrombosis 2 (3.1%)
Central venous catheter infection 16 (24.6%)
Chronic systemic inflammation (% of the follow-up)
0 34 (52.3%)
25% 8 (12.3%)
50% 8 (12.3%)
75% 9 (13.8%)
100% 6 (9.2%)
Hospitalization
No. of pts. and % 29 (44.6%)
No. of days in hospitalized patients 23.8718.2 (2–67)
HPN¼home parenteral nutrition.
aCholecystectomy, 3; intestinal stricturoplasty, 1.
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Z-score at the 1st BMD assessment: R ¼ 0:286; P ¼
0:044:
A backward multiple regression analysis was
performed using the variations of the LS BMD Z-
score as a dependent variable and as independent
variables those parameters, shown in Tables 5–7,
which significantly differed between the subgroups
of patients with decreased or increased/unchanged
BMD Z-scores. Only the degree of rehabilitation
(P ¼ 0:098), sex (P ¼ 0:070) and age at starting HPN
(P ¼ 0:056) entered in the system. After removing
the rehabilitation degree, the relationships be-
tween LS BMD Z-score changes and sex (P ¼ 0:021)
and age at starting HPN (P ¼ 0:022) were statisti-
cally significant and the equation of the multiple
linear regression model was: LS BMD Z-score
change¼ 0.9450–0.0088 age at starting HPNF
0.2772 sex (male¼ 1; female¼ 2) (F-ratio¼ 7.11;
P ¼ 0:001), adjusted R2 of the model was 0.203.
The last backward multiple regression analysis was
repeated replacing the annualized percent BMD
changes for the Z-score changes as a dependent
variable. The results confirmed sex (Po0:001) and
age at starting HPN (P ¼ 0:007) as the only
variables which entered in the system: annualized
percent LS BMD change¼ 11.22–0.1080 age at
starting HPNF4.287 sex (male¼ 1; female¼ 2)
(F-ratio¼ 13.65; Po0:001), adjusted R2 0.340.
The relationship between age at starting HPN and
age at time of entering in the study (1st BMD
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Table 3 Characteristics of the HPN programme of the oral diet and of intestinal absorption during the follow-up
(between the 1st BMD and the 2nd BMD).
Days of HPN infusion per week 5.5471.47 (2–7)
Hours of HPN infusion per day 13.372.7 (9.0–24.0)
Nutrients in the HPN (per day of infusion)
Volume (ml) 21467916 (1000–7000)
Amino acids (g/kg body weight) 1.0670.44 (0.0–2.06)
Glucose (g/kg body weight) 4.0271.53 (1.36–8.77)
Lipids (g/kg body weight) 0.8270.56 (0.0–2.37)
Na (mmol) 117789 (11–450)
Ca (mmol) 7.8672.74 (3.0–19.0)
Phosphate (mmol) 16.978.5 (0–40)
Ca/phosphate (mmol/mmol) 0.5870.45 (0.10–3.40)
Mg (mmol) 9.7473.40 (3.0–20)
Acetate (mmol) 109759 (0–257)
Micronutrients (no. per week)a
Vitamins 4.2772.28 (0–7)
Trace metals 3.0972.34 (0–7)
Total energy by HPN/BEE (per week)b 0.9170.39 (0.10–1.85)
Oral energy intake (kJ/day) 666472323 (1674–11586)
Type of oral diet (no. of pts. and %)
Free 27 (41.5%)
Low Fat 2 (3.1%)
Low fibre 3 (4.6%)
Liquid 30 (30.8%)
Clear liquid 11 (16.9%)
No oral food 2 (3.1%)
Fat malabsorption (no. of pts. and %)
o 7% 11 (16.9%)
7–25% 10 (15.4%)
26–50% 31 (47.7%)
450% 13 (20.0%)
BMD¼bone mineral density.
aCommercial preparations for parenteral nutrition.
bkJ/day of infusion no. of infusions per week/BEE 7.
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assessment) was R ¼ 0:938 (Po0:001). Excluding
age at starting HPN from the above multiple
regressions, the results were: LS BMD Z-score
change¼ 0.9402–0.0078 age at the 1st BMDF
0.2633 sex (male¼ 1; female¼ 2) (P ¼ 0:056
for age at 1st BMD, P ¼ 0:026 for sex; F-
ratio¼ 6.07, P ¼ 0:004; adjusted R2 ¼ 0:171; for
the model); annualized percent LS BMD
change¼ 11.60–0.0953 age at the 1st BMDF
4.286 sex (male¼ 1; female¼ 2) (P ¼ 0:027
for age at 1st BMD, Po0:001 for sex; F-
ratio¼ 11.80, Po0:001; adjusted R2 ¼ 0:306 for
the model).
Lumbar spine BMD changes between baseline
BMD and the 1st BMD
Baseline BMD was available for eight patients who
had the LS BMD assessed within 1 month from
starting HPN: males five and females three; age at
starting HPN, 45.8714.7 years (24–63); mesenteric
ischaemia 4, radiation enteritis 1, volvolus 1,
others 2; short bowel 8. The LS BMD Z-score was
41 in three patients, between 1 and 2 in four
patients and o2 in one patient. The relationship
between the age at starting HPN and the baseline
Z-score was positive: R ¼ 0:305; P ¼ 0:463: The
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Table 4 Variations of the BMD Z-scores and symptoms of bone disease during the follow-up (between the 1st BMD
and the 2nd BMD.
BMD Z-score variations at lumbar spine (50 pts.)
Absolute (2nd BMD–1st BMD) þ 0.1570.43 (0.82 to þ 1.30)
Increase or no change (no. and %)a 32 (64.0%)
Decrease (no. and %) 18 (36.0%)
BMD Z-score variations at femoral neck (44 pts.)
Absolute (2nd BMD–1st BMD) þ 0.0570.47 (1.70 to þ 0.98)
Increase or no change (no. and %)a 24 (54.5%)
Decrease (no. and %) 20 (45.5%)
Bone pain during the follow-up (no. of patients and %) 26 (40.0%)
Fractures during the follow-up (no. of patients and %) 3 (4.6%)
BMD Z-scores in patients with bone pain or fracture (no. 27)
Lumbar spine Z-score (17 pts.)
Baseline 1.5471.35 (4.00 to þ 0.99)
Absolute variation (2nd BMD–1st BMD) 0.0370.35 (0.82 to þ 0.76)b
Increase (no. of pts. and %) 9 (52.9%)
Decrease (no. of pts. and %) 8 (47.1%)
Femoral neck Z-score (19 pts.)
Baseline 1.0871.72 (3.60 to þ 2.50)
Absolute variation (2nd BMD–1st BMD) 0.0470.50 (1.70 to þ 0.75)
Increase (no. of pts. and %) 10 (52.6%)
Decrease (no. of pts. and %) 9 (47.4%)
BMD Z-scores in asymptomatic patients (no. 38)
Lumbar spine Z-score (33 pts.)
Baseline 1.1771.37 (3.42 to þ 1.45)
Absolute variation (2nd BMD–1st BMD) þ 0.2470.44 (0.56 to þ 1.30)
Increase (no. of pts. and %) 23 (69.7%)
Decrease (no. of pts. and %) 10 (30.3%)
Femoral neck Z-score (25 pts.)
Baseline 0.8371.19 (3.10 to þ 2.48)
Absolute variation (2nd BMD–1st BMD) þ 0.1270.41 (0.60 to þ 0.98)
Increase (no. of pts. and %) 14 (56.0%)
Decrease (no. of pts. and %) 11 (44.0%)
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
aNo change: at lumbar spine, one patient; at femoral neck, two patients.
bP ¼ 0:039 vs. asymptomatic patients.
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mean variation of the Z-score wasF0.1571.01
between the baseline BMD and the 1st BMD. The
relationship between the age at starting HPN and
the Z-score variations was negative: R ¼ 0:256;
P ¼ 0:540:
Discussion
The results of this short-term follow-up study in an
adult patient population receiving HPN for chronic
benign intestinal failure showed an increase of the
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Table 5 1st BMD Z-score, annualized percent BMD change, type of DEXA instrument, duration of the follow-up
(between the 1st BMD and the 2nd BMD) and general, life style and primary disease characteristics in the patient
subgroups on the basis of the FN BMD Z-score variation.
Femoral neck BMD Z-score variation
Decreased (20 pts.) Increased/unchanged (24 pts.) P
DEXA instrument (no. and % of pts.) 0.599
Hologic 4 (20.0%) 5 (20.8%)
Norland 8 (40.0%) 12 (50.0%)
Lunar 8 (40.0%) 7 (29.2%)
Annualized BMD changes (%/year) 3.5874.67 4.1371.52 o 0.001
1st BMD Z-score 0.6371.41 1.2871.52 0.140
Duration of follow-up (months) 17.576.2 17.075.2 0.758
Age at the 1st BMD (years) 55.5716.7 54.4717.1 0.924
Females (no. and % of pts.) 12 (60.0%) 16 (66.7%) 0.647
Post-menopausal (no. and % of females) 8 (66.7%) 12 (75.0%) 0.629
BMI (kg/m2) 21.471.8 21.171.9 0.089
Variation of BMI (kg/m2) 0.0571.87 0.8171.97 0.187
No. of significant variations of body
weight (75 kg)
1.4072.03 1.2071.93 0.671
Rehabilitation degree at the 2nd BMD
(best to poorest: 1–4)
1.7570.85 1.6670.86 0.660
No. of variations of rehabilitation degree 0.1070.30 0.0470.20 0.449
Duration of HPN (months) 75.4748.7 108.7780.1 0.171
Age at starting HPN (years) 48.8718.0 45.5718.7 0.450
Primary disease (no. and %) 0.022
Crohn’s 4 (20.0%) 7 (20.2%)
Mesenteric ischaemia 13 (65.0%) 6 (25.5%)
Others 3 (15.0%) 11 (45.8%)
Duration of primary disease before
starting HPN (months)
37.4753.0 61.5770.2 0.115
Short bowel (no. and % of pts.) 19 (95.0%) 198 (79.2%) 0.127
Cigarette smoking (no. and % of pts.) 3 (15.0%) 5 (20.8%) 0.617
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
DEXA¼dual-energy-X-ray absorptiometry.
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BMD Z-score in more than one-half of the patients
and indicated that age and sex were the only
clinical risk factors independently correlated with
the changes in the LS BMD Z-score, which were
negative in older patients and females. Moreover,
the positive correlation between the age at starting
HPN and the LS BMD Z-score, observed in the
previous study6 and confirmed in the present one,
suggests that patients who developed intestinal
failure at a younger age had a lower spine BMD at
starting HPN, but they also showed a greater
probability of increasing axial bone calcium con-
tent during the treatment than patients who
started HPN at an older age. The study protocol
was based on the analysis of the Z-score, which
allows the comparison of the patient BMD to normal
BMD values corrected for sex and age. Because of
the multicentre design of the study, different DEXA
instruments were used and the Z-score evaluation
relied on different data bases. In order to verify if
this had interfered with the results, the annualized
percent BMD changes were also analysed. The
results confirmed and strengthened those obtained
by the BMD Z-score even though the use of a
phantom to calibrate all the instruments together
would have been the most appropriate methods to
avoid bias due to the use of different instruments.
In spite of many potential HPN-related mechan-
isms for the development of a metabolic bone
disease, the BMD significantly increased at the axial
bone and remained stable at the appendicular
bone. Also the results of the previously published
longitudinal studies performed by single centre and
including small patient groups showed that long-
term HPN do not necessarily cause a worsening of
bone health and in some cases may be beneficial.7–10
Foldes et al.7 studied 10 patients. After a follow-up
period of 5–19 months cancellous and cortical BMD
significantly decreased in eight and in seven
patients, respectively, and increased or remained
stable in the others. The initial BMD was lower in
patients in whom HPN was started several years
after the diagnosis of intestinal disease, but the
rate of change of BMD values did not differ between
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Table 6 Drugs and morbidity during follow-up (between the 1st BMD and the 2nd BMD) in the patient subgroups
on the basis of the FN BMD Z-score variations.
Femoral neck BMD Z-score variation
Decreased (20 pts.) Increased/unchanged (24 pts.) P
Patients receiving drugs (no. and %)a
Corticosteroids 2 (10.0%) 3 (12.5%) 0.794
Immunosuppressive 1 (5.0%) 0 0.926
Diuretics 3 (15.0%) 3 (12.5%) 0.809
Oestrogenic hormones 1 (5.0%) 1 (4.2%) 0.894
Oral calcium 6 (30.0%) 6 (25.0%) 0.710
Bisphosphonate 2 (10.0%) 6 (25.0%) 0.198
Vitamin D, i.m. 4 (20.0%) 6 (25.0%) 0.693
Vitamin D, oral 8 (40.0%) 6 (25.0%) 0.287
Chronic renal failure (no. of pts. and %) 2 (10.0%) 4 (16.7%) 0.521
Surgical intervention (no. of pts. and %) 1 (5.0%) 2 (8.3%) 0.662
Deep vein thrombosis (no. and %) 0 0 1.00
CVC infection (no./patient) 0.4570.88 0.1670.38 0.383
Chronic systemic inflammation
(% of follow-up/patient) 27.5739.6 33.3734.3 0.514
Hospitalization
No. and % of patients 7 (35.0%) 12 (50.0%) 0.317
No. of days (in hospitalized patients) 23.2713.6 25.5721.1 0.832
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
CVC¼ central venous catheter.
aPatients receiving drugs for at least 33% of the duration of the follow-up.
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patients with and without prolonged intestinal
disease before starting HPN. Over a period of 6–28
months, Shike et al.8 found a significant decrease in
bone mass in five patients whose bone mass was
initially in the normal range and a not significantly
increase in nine patients with initial values below
normal. Saitta et al.9 studied 14 patients over a
period of 7–61 months. On entry into the study, the
BMD measures at both cancellous and cortical bone
were negatively correlated with the duration of
HPN. At the follow-up assessment, BMD remained
stable in nine, increased in two and decreased in
three patients. In the whole group, the changes of
BMD at the cortical bone negatively correlated with
the duration of the follow-up. No correlation was
observed with the changes at the cancellous bone.
Staun et al.10 studied 15 patients with inflamma-
tory bowel disease (13 Crohn’s disease) receiving
HPN for short bowel syndrome, over a period of 20–
106 months. On entry into the study, both mean LS
and FN BMD Z-score were significantly reduced, but
Z-score values did not correlate with the duration
of the HPN. During the follow-up, LS and femoral
neck BMD Z-score decreased in eight and nine
patients, respectively, and increased or was un-
changed in the other patients. At both sites, the
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Table 7 Characteristics of the HPN programme, oral diet and intestinal function during follow-up (between the
1st BMD and the 2nd BMD) in the patient subgroups on the basis of FN BMD Z-score variations.
Femoral neck BMD Z-score variation
Decreased (20 pts.) Increased/unchanged (24 pts.) P
Days of HPN infusion per week 5.5071.57 5.3371.5 0.830
Hours of HPN infusion per day 13.472.5 13.873.0 0.854
Nutrients in the HPN (per day of infusion)
Volume (ml) 21377758 21087708 0.934
Amino acids (g/kg body weight) 0.9770.40 0.9670.35 0.804
Glucose (g/kg body weight) 3.7471.37 4.0871.38 0.486
Lipids (g/kg body weight) 0.8670.58 0.7270.55 0.670
Na (mmol) 103781 106763 0.743
Ca (mmol) 7.6572.41 7.3371.99 0.836
Phosphate (mmol) 15.179.2 16.676.9 0.585
Ca/Phosphate (mmol/mmol) 0.5670.25 0.5670.32 0.715
Mg (mmol) 9.8573.18 8.9172.39 0.451
Acetate (mmol) 93.64771.9 101.8756.3 0.504
Micronutrients (no. per week)a
Vitamins 4.2272.23 3.9572.40 0.773
Trace metals 3.4072.52 2.9772.65 0.591
Total energy by HPN/BEE (per week)b 0.8570.38 0.8670.37 0.887
Oral energy intake (Calories/day) 16217615 15527566 0.563
Type of oral diet (no. of pts. and %) 0.601
Free 12 (60.0%) 11 (45.8%)
Low fat 0 1 (4.2%)
Low fibre 2 (10.0%) 1 (4.2%)
Liquid 4 (20.0%) 6 (25.0%)
Clear liquid 2 (10.0%) 3 (12.5%)
No oral food 0 2 (8.3%)
Fat malabsorption (no. of pts. and %) 0.783
o7% 3 (15.0%) 4 (16.7%)
7–25% 2 (10.0%) 5 (20.8%)
26–50% 10 (50.0%) 10 (41.7%)
450% 5 (25.0%) 5 (20.8%)
aCommercial preparations for parenteral nutrition.
bCalories per day of infusion no. of infusions per week/BEE 7).
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Z-score changes did not correlate with the duration
of the HPN. Our data obtained by means of
densitometry differs from those obtained from
bone histology. The present follow-up and our
previous cross-sectional investigation6 were per-
formed on patients who underwent either routine
BMD assessment or BMD assessment for participa-
tion in the studies. On the contrary, almost all the
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Table 8 1st BMD Z-score, annualized percent BMD change, type of DEXA instrument, duration of the follow-up
(between the 1st BMD and the 2nd BMD), and general, life style and primary disease characteristics in the patient
subgroups on the basis of the LS BMD Z-score variation.
Lumbar spine BMD Z-score variation
Decreased (18 pts.) Increased/unchanged (32 pts.) P
DEXA instrument (no. and % of pts.) 0.834
Hologic 5 (27.8%) 8 (25.0%)
Norland 8 (44.4%) 15 (46.9%)
Lunar 5 (27.8%) 9 (28.1%)
Annualized BMD changes (%/year) 4.5472.91 3.0773.47 o 0.001
1st BMD Z-score 0.7171.43 1.8571.21 0.005
Duration of follow-up (months) 17.975.9 17.875.9 0.895
Age at the 1st BMD (years) 55.4712.0 45.4714.6 0.018
Females (no. and % of pts.) 15 (83.3%) 12 (37.5%) 0.005
Post-menopausal (no. and % of females) 9 (60.0%) 7 (58.3%) 1.00
BMI (kg/m2) 21.272.7 20.472.5 0.312
Variation of BMI (kg/m2) 0.5871.93 0.2871.33 0.159
No. of significant variations of body
weight (75 kg)
1.2271.96 1.0971.87 0.768
Rehabilitation degree at the 2nd BMD
(best to poorest: 1–4)
1.9470.94 1.3470.54 0.015
No. of variations of rehabilitation degree 0.1170.32 0.0670.25 0.547
Duration of HPN (months) 91.7772.9 97.5763.2 0.538
Age at starting HPN (years) 48.6713.9 37.8714.7 0.010
Primary disease (no. and %) 0.044
Crohn’s 2 (11.1%) 11 (34.4%)
Mesenteric ischaemia 12 (66.7%) 10 (31.3%)
Others 4 (22.2%) 11 (34.4%)
Duration of primary disease before
starting HPN (months)
16.5728.1 59.7768.6 0.008
Short bowel (no. and % of pts.) 17 (94.4%) 28 (87.5%) 0.768
Cigarette smoking (no. and % of pts.) 3 (16.6%) 4 (12.5%) 1.00
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
DEXA¼dual-energy X-ray absorptiometry.
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studies12–15 on bone histology in patients on HPN
without evidence of excessive aluminium exposure
were performed on patients having symptoms and/
or biochemical signs of bone disease. These
investigations showed the presence of either
osteomalacia or osteoporosis associated with a
low bone formation rate and hypercalciuria in most
of the patients. A direct pathogenetic role of HPN
was hypothesized through toxicity from daily
intravenous infusion of vitamin D,12 hypercalciuria
induced by the intravenous infusion of nutrients,13
the development of an impaired PTH secretion or a
decreased response to the hormone.14 Other
hypotheses were excess (strontium, fluoride, cad-
mium) or deficiency (zinc, copper, manganese) of
micronutrients,13,15 which are considered to play a
role in bone metabolism or a direct role of HPN in
inducing the release and/or regulating the activity
of cytokines known to impair bone metabolism.16
The comparison of the results obtained from
histology with those obtained by means of densito-
metry suggests that, while a single patient may
develop an HPN-related impairment of bone meta-
bolism, the risk of an HPN-related decrease of BMD
is not evident in the patient population. Alternative
explanations may be the lack of bone densitometry
in detecting qualitative bone changes.17 Never-
theless, our findings indicate that, in patients on
HPN, bone symptoms predict a decrease of BMD and
that BMD values may predict the risk of bone
fractures, in agreement with the World Health
Organization diagnostic categories of bone disease,
based on the measurement of the BMD, which were
established for post-menopausal women in whom
osteoporosis is by far the most common bone
disease.18
The results of the multiple regression analysis
showed that general factors, but not underlying
disease or HPN-related factors, were indepen-
dently associated with the variations of the LS
BMD during HPN. As in the general population,18,19
female sex and ageing were the main clinical risk
factors for a decrease in the BMD at the LS
(trabecular bone). The two major determinants of
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Table 9 Drugs and morbidity during follow-up (between the 1st BMD and the 2nd BMD) in the patient subgroups
on the basis of the LS BMD Z-score variations.
Lumbar spine BMD Z-score variation
Decrease (18 pts.) Increase/unchanged (32 pts.) P
Patients receiving drugs (no. and %)a
Corticosteroids 1 (5.6%) 4 (12.5%) 0.768
Immunosuppressive 0 1 (3.1%) 1.00
Diuretics 1 (5.6%) 0 0.768
Oestrogenic hormones 3 (16.7%) 0 0.078
Oral calcium 4 (22.2%) 11 (34.4%) 0.563
Bisphosphonate 4 (22.2%) 6 (18.8%) 1.00
Vitamin D, i.m. 4 (22.2%) 4 (12.5%) 0.618
Vitamin D, oral 3 (16.7%) 6 (18.8%) 1.00
Chronic renal failure (no. of pts. and %) 2 (11.1%) 3 (9.4%) 1.00
Surgical intervention (no. of pts. and %) 1 (5.6%) 2 (6.3%) 1.00
Deep vein thrombosis (no. and %) 2 (11.1%) 0 0.241
CVC infection (no./patient) 0.8971.13 0.1670.45 0.002
Chronic systemic inflammation
(% of follow-up/patient) 20.9733.5 26.6733.6 0.514
Hospitalization
No. and % of patients 13 (72.2%) 9 (28.1%) 0.007
No. of days (in hospitalized patients) 23.8716.0 17.0714.9 0.216
Z-score¼ number of standard deviations from mean BMD normal values corrected for sex and age.
CVC¼ central venous catheter.
aPatients receiving drugs for at least 33% of the duration of the follow-up.
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risk in the development of osteoporosis are peak
bone mass and rate of bone loss.18,19 Thus, women
are more likely to have osteoporosis than men
because of a lower peak bone mass and a greater
rate of bone loss, especially after menopause. The
rate of bone loss also rises in men in old age. These
two determinants are influenced by a number of
genetic and environmental factors, although ge-
netic factors play the major role including that
indictating how an individual will respond to
various exogenous stressors.18,19 This may explain
why sex and age at starting HPN were the only
clinical factors independently related to the varia-
tions of the LS BMD Z-score and why, in our model,
these two factors justified only 20% of the varia-
tions of the Z-score (34% of the annualized percent
BMD change), indicating that other factors con-
tributing to bone loss were not detected by or
included in our investigation. Schulte et al.20
showed that the extent of bone loss in patients
with inflammatory bowel disease was associated
with genetic variations of interleukin (IL)-1 recep-
tor antagonist and IL-6 genes, but neither the
clinical parameters nor biochemical markers of
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Table 10 Characteristics of the HPN programme, oral diet and intestinal function during follow-up (between the
1st BMD and the 2nd BMD) in the patient subgroups on the basis of LS BMD Z-score variations.
Lumbar spine BMD Z-score variation
Decrease (18 pts.) Increase/unchanged (32 pts.) P
Days of HPN infusion per week 6.0671.47 5.3871.41 0.060
Hours of HPN infusion per day 13.973.6 13.072.4 0.641
Nutrients in the HPN (per day of infusion)
Volume (ml) 240171331 21327740 0.701
Amino acids (g/kg body weight) 0.9670.46 1.0570.35 0.486
Glucose (g/kg body weight) 3.9171.78 4.4271.42 0.104
Lipids (g/kg body weight) 0.8370.69 0.8170.55 0.960
Na (mmol) 125795 120799 0.494
Ca (mmol) 7.2271.99 8.1372.45 0.320
Phosphate (mmol) 17.378.7 17.079.1 0.935
Ca/phosphate (mmol/mmol) 0.4970.26 0.5470.22 0.411
Mg (mmol) 9.4472.68 10.0373.61 0.919
Acetate (mmol) 95.127 55.3 104.7762.5 0.643
Micronutrients (no. per week)a
Vitamins 3.6972.70 4.2872.25 0.505
Trace metals 3.0672.60 3.5672.44 0.526
Total energy by HPN/BEE (per week)b 0.9670.45 0.8970.35 0.585
Oral energy intake (calories/day) 15117633 16987556 0.157
Type of oral diet (no. of pts. and %) 0.799
Free 10 (55.6%) 17 (53.1%)
Low fat 1 (5.6%) 1 (3.1%)
Low fibre 0 2 (6.3%)
Liquid 3 (16.7%) 8 (25.0%)
Clear liquid 3 (16.7%) 3 (9.4%)
No oral food 1 (5.6%) 1 (3.1%)
Fat malabsorption (no. of pts. and %) 0.142
o 7% 1 (5.6%) 4 (12.5%)
7–25% 2 (11.1%) 6 (18.8%)
26–50% 10 (55.6%) 18 (56.3%)
450% 5 (27.8%) 4 (12.5%)
aCommercial preparations for parenteral nutrition.
bCalories per day of infusionNo. of infusions per week/BEE 7.
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bone metabolism predicted the rate of bone loss.
They suggested that the genetic equipment of the
bone determines the bone vulnerability to different
systemic stress factors, thus determining patient
risk for bone loss. Similar mechanisms may be
hypothesized in HPN patients. Animal studies have
shown that parenteral nutrition enhances the
catabolic effects of tumour necrosis factor
(TNF)aU21 Increased serum and urine concentra-
tions of IL-6 and soluble TNF receptor II, not
associated with clinical and biochemical signs of
inflammation, were observed in patients on long-
term HPN.22 Increased mRNA expression for inflam-
matory cytokines (IL-1, IL-6, TNF-a) in the intestine
of parenterally fed rats have been demonstrated.23
These findings would suggest that patients may
differ in the way in which they react to HPN-related
factors interfering with bone metabolism as well as
to measures for preventing and treating bone
disease. Indeed, our patients subgroups with
increased or decreased BMD Z-scores did not differ
with respect to the drugs received during the
follow-up and a randomized controlled study on the
effect of bisphosphonate clodronate on BMD and
markers of bone turnover of patients on HPN gave
some results which differed from what would have
been expected.24 No correlation was found be-
tween the bone turnover rate and the increase in
BMD, a finding which is in contrast with that
observed in post-menopausal osteoporosis, in which
patients with a high rate of bone turnover respond
to the treatment better.25 Clodronate caused a
decrease of the markers of bone resorption but also
an unexplained increase of osteocalcin, the marker
of bone formation.
Taken together, the results of the previous cross-
sectional study6 and of the present follow-up
suggest that patients who developed intestinal
failure at a younger age had a lower spine BMD
when starting HPN, but they also showed a greater
probability of increasing the axial calcium content
during the treatment. Causes of intestinal failure
occurring early in life may be associated with a
reduced BMD through mechanisms directly increas-
ing bone resorption, as in Crohn’s disease, or
indirectly decreasing bone formation, as in mal-
nutrition due to reduced dietary intake or malab-
sorption.26 The improvement of the nutritional
status associated with HPN may allow the recovery
of axial BMD in younger patients.27 On the other
hand, the main cause of intestinal failure in older
patients is mesenteric ischaemia which, in the
majority of cases, is a sudden event occurring in
well-nourished subjects who may have no factor
interfering with bone metabolism other than
ageing. In the individual patient, the BMD varia-
tions were not consistent between the LS and the
FN. The known differences between trabecular and
cortical bone remodelling19 may explain these data
and why LS and FN BMD changes were not
associated with the same risk factors. It should
also be considered that bone turnover was not
investigated in the present study. Considering the
previous findings suggesting a potential pathoge-
netic role of intravenous vitamin D12 and the
development of impaired PTH secretion or func-
tion14 in patients on long-term HPN, the involve-
ment of these mechanisms cannot be excluded by
the present investigation. Follow-up studies with
measurements of biochemical markers of bone
turnover in patients on long-term HPN are re-
quired.
In conclusion, this study did not show a signifi-
cant decrease of the BMD Z-score in an adult
patient population on long-term HPN and indicated
that BMD variations were related to general clinical
risk factors, such as age and sex, rather than to
HPN-related factors. Studies investigating both the
biochemical markers of bone turnover and the
genetic risk factors for bone loss in patients
receiving HPN could clarify the impact of HPN on
bone metabolism.
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